Brief: Aelis Farma Announces Positive Results From Its Trials Of AEF0217 In Volunteers

Aelis Farma SA

15/11/2022 17:25

Nov 15 (Reuters) - Aelis Farma SA  AELIS.PA :
    * AELIS FARMA ANNOUNCES POSITIVE RESULTS FROM ITS SAFETY
TRIALS IN
HEALTHY VOLUNTEERS AND AUTHORIZATION TO START FIRST TRIAL IN
PEOPLE WITH DOWN SYNDROME WITH AEF0217, ITS DRUG CANDIDATE FOR
TREATMENT OF COGNITIVE DISORDERS
    * AEF0217 IS BEING DEVELOPED AS FIRST TREATMENT FOR
COGNITIVE
DEFICITS CAUSED BY A HYPERACTIVITY OF CB1 RECEPTOR, FIRST
INDICATION BEING THOSE LINKED TO DOWN SYNDROME (TRISOMY 21),
WHICH IS CURRENTLY A MAJOR UNMET MEDICAL NEED
    * ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL IS EXPECTED TO
START
BEFORE END OF YEAR
    * SINGLE DOSE AND MULTIPLE ASCENDING DOSE TRIAL OF AEF0217
HAS
DEMONSTRATED SAFETY, TOLERABILITY AND GOOD BIOAVAILABILITY OF
AEF0217 IN HEALTHY VOLUNTEERS
    * ON BASIS OF THESE POSITIVE RESULTS, AEMPS, SPANISH AGENCY
FOR
MEDICINES AND MEDICAL DEVICES, HAS AUTHORIZED A PHASE 1/2
CLINICAL TRIAL IN ADULTS WITH TRISOMY 21

Source text for Eikon:  ID:nBwQspwYa 
Further company coverage:  AELIS.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))